Posted inCardiology news
NOAC Monotherapy After Drug‑Eluting Stent: Safer and at Least as Effective as NOAC Plus Clopidogrel in AF Patients ≥1 Year After PCI
In the ADAPT AF‑DES randomized trial, NOAC monotherapy in AF patients with drug‑eluting stents implanted ≥1 year earlier reduced bleeding and was noninferior—and numerically superior—for a composite of ischemic and bleeding outcomes versus NOAC plus clopidogrel at 12 months.